Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial/venous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age over 18 years. 2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography. 3. Availability of complete clinical and follow-up information required for the study. 4. Availability of blood and/or thrombus biological samples. 5. Voluntary written willing to sign a consent form signed by the patient or their family (1) For retrospectively enrolled patients, a "broad willing to sign a consent form" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the willing to sign a consent form. (2) For prospectively enrolled patients, willing to sign a consent form for this study was signed at the time of enrollment by the patient or their family. Who Should NOT Join This Trial: 1. Patients for whom biological samples cannot be obtained; 2. Patients or their family members who refuse to sign the willing to sign a consent form form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Age over 18 years. 2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography. 3. Availability of complete clinical and follow-up information required for the study. 4. Availability of blood and/or thrombus biological samples. 5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a "broad informed consent" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent. (2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family. Exclusion Criteria: 1. Patients for whom biological samples cannot be obtained; 2. Patients or their family members who refuse to sign the informed consent form.

Treatments Being Tested

OTHER

Not applicable- observational study

Intervention is not applicable

Locations (5)

The First Affiliated Hospital of Shihezi University
Wuhu, Anhui, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Affiliated Hospital of Shandong University of Traditional Chinese Medicine Hospital
Jinan, Shandong, China
The First Affiliated Hospital of zhengzhou University
Henan, Zhengzhou, China
Capital medical university of Beijing Tiantan Hospital
Beijing, China